Cargando…
Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease with a global prevalence of 25%. However, the medicines approved by the FDA or EMA are still not commercially available for the treatment of NAFLD. The NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammas...
Autores principales: | Ma, Ji, Li, Maoru, Yang, Tingting, Deng, Yang, Ding, Yadong, Guo, Tiantian, Shang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10218527/ https://www.ncbi.nlm.nih.gov/pubmed/37240141 http://dx.doi.org/10.3390/ijms24108795 |
Ejemplares similares
-
Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020) -
Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
por: Piippo, Niina, et al.
Publicado: (2018) -
Pharmacokinetic comparison of quercetin, isoquercitrin, and quercetin-3-O-β-D-glucuronide in rats by HPLC-MS
por: Yin, Hongli, et al.
Publicado: (2019) -
Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
por: Xu, Guang, et al.
Publicado: (2021) -
Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases
por: Shi, Wei, et al.
Publicado: (2020)